Alejo Lingua

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

Luis Paz‐Ares, Tudor–Eliade Ciuleanu, Manuel Cobo et al. · The Lancet Oncology · 2021 · 1.3K citations

Non-small-cell Lung Cancer, Medicine, Pharmacology +6

First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update

Martin Reck, Tudor–Eliade Ciuleanu, Manuel Cobo et al. · ESMO Open · 2021 · 184 citations · Full text

Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial

Robert J. Motzer, Paul Russo, Viktor Grünwald et al. · The Lancet · 2023 · 159 citations · Full text

Urology, Surgical Oncology, Genitourinary Cancer +7

First-Line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic NSCLC in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations

Luis Paz‐Ares, Tudor–Eliade Ciuleanu, Manuel Cobo et al. · Journal of Thoracic Oncology · 2022 · 92 citations

LBA4 Adjuvant nivolumab plus ipilimumab (NIVO+IPI) vs placebo (PBO) for localized renal cell carcinoma (RCC) at high risk of relapse after nephrectomy: Results from the randomized, phase III CheckMate 914 trial

Robert J. Motzer, Paul Russo, Viktor Gruenwald et al. · Annals of Oncology · 2022 · 37 citations

Urology, Surgical Oncology, Genitourinary Cancer +7